Dr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis ...

Company awaiting comments from FDA by the end of August 2026 on protocol submitted for planned Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis.

Operator: Good morning, and welcome to Alico's Third Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, today's call is being recorded. I would now like to turn the call over to your ...

The reason to be bullish for this program, which I'm going to go over in detail below, is because it was able to initiate a rolling New Drug Application [NDA] of ALXN1840 for the treatment of these ...

ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early AdoptionRusfertide NDA under Priority Review for ...

Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced the MIUDELLA ® (copper intrauterine system) Risk ...

Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - ...

Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference ...

Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a clinica ...

Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies for multiple neuroinflammatory ...

On 9 February 2026, the chief executive of pan-African telecoms operator Paratus Group announced the activation of the terrestrial fibre backbone G2M (Goma-to-Mombasa), a 2,000 km route directly ...

Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced securing $60 million in funding, a ...